[go: up one dir, main page]

WO2011107921A3 - Composition de milnacipran à libération modifiée - Google Patents

Composition de milnacipran à libération modifiée Download PDF

Info

Publication number
WO2011107921A3
WO2011107921A3 PCT/IB2011/050825 IB2011050825W WO2011107921A3 WO 2011107921 A3 WO2011107921 A3 WO 2011107921A3 IB 2011050825 W IB2011050825 W IB 2011050825W WO 2011107921 A3 WO2011107921 A3 WO 2011107921A3
Authority
WO
WIPO (PCT)
Prior art keywords
milnacipran
modified release
release composition
preparation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/050825
Other languages
English (en)
Other versions
WO2011107921A2 (fr
Inventor
Sumit Madan
Vinod Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2011107921A2 publication Critical patent/WO2011107921A2/fr
Publication of WO2011107921A3 publication Critical patent/WO2011107921A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une composition à libération modifiée comprenant du milnacipran ou ses sels pharmaceutiquement acceptables, et un procédé pour sa préparation.
PCT/IB2011/050825 2010-03-04 2011-02-25 Composition de milnacipran à libération modifiée Ceased WO2011107921A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN479/DEL/2010 2010-03-04
IN479DE2010 2010-03-04

Publications (2)

Publication Number Publication Date
WO2011107921A2 WO2011107921A2 (fr) 2011-09-09
WO2011107921A3 true WO2011107921A3 (fr) 2012-07-26

Family

ID=44169175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/050825 Ceased WO2011107921A2 (fr) 2010-03-04 2011-02-25 Composition de milnacipran à libération modifiée

Country Status (1)

Country Link
WO (1) WO2011107921A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793683B (zh) * 2012-09-04 2013-04-17 海南康虹医药科技开发有限公司 一种含左旋米那普仑的缓释组合物及其制备方法
EP3199145B1 (fr) 2016-01-28 2018-10-17 G.L. Pharma GmbH Formule stabilisee d'une preparation de fer/d'acides foliques
EP3199167A1 (fr) 2016-01-28 2017-08-02 G.L. Pharma GmbH Medicament destine a traiter des carences en fer et en acide folique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037190A2 (fr) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Compositions de milnaciprane a liberation modifiee
WO2004039361A1 (fr) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Compositions a liberation intermittente de milnaciprane
WO2004067039A1 (fr) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
WO2005117872A2 (fr) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Antagonistes de snri-nmda a double action utilises pour traiter des troubles genito-urinaires
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037190A2 (fr) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Compositions de milnaciprane a liberation modifiee
WO2004039361A1 (fr) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Compositions a liberation intermittente de milnaciprane
WO2004067039A1 (fr) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
WO2005117872A2 (fr) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Antagonistes de snri-nmda a double action utilises pour traiter des troubles genito-urinaires
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation

Also Published As

Publication number Publication date
WO2011107921A2 (fr) 2011-09-09

Similar Documents

Publication Publication Date Title
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2014014835A8 (fr) Formes cristallines d'un inhibiteur de la prolyl hydroxylase
WO2011130615A3 (fr) Synthèse de lacosamide
WO2011131943A3 (fr) Compositions pharmaceutiques
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
WO2012068441A3 (fr) Sels d'intedanib et leurs formes à l'état solide
WO2010117738A3 (fr) Formes à l'état solide de sels de sitagliptine
WO2011057262A3 (fr) Traitement des infections par des antagonistes du récepteur tp
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2012016683A3 (fr) Forme galénique orale de prégabaline
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
WO2012085927A3 (fr) Compositions de tadalafil
WO2011079193A3 (fr) Préparation de la bendamustine et de ses sels
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
WO2010065586A3 (fr) Préparation de capécitabine
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
WO2011023954A3 (fr) Formes polymorphes de manidipine
PH12013500210A1 (en) Highly crystalline valsartan
WO2012018791A3 (fr) Préparation de chlorhydrate de prasugrel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11712677

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11712677

Country of ref document: EP

Kind code of ref document: A2